Empaglifloz/Linaglip/Metformin
Brand name: Trijardy Xr
Rank #391 of 500 drugs by total cost
$23.9M
Total Cost
28,001
Total Claims
$23.9M
Total Cost
747
Prescribers
$852
Cost per Claim
3,664
Beneficiaries
40,622
30-Day Fills
$32K
Avg Cost/Provider
37
Avg Claims/Provider
About Empaglifloz/Linaglip/Metformin
Empaglifloz/Linaglip/Metformin (sold as Trijardy Xr) was prescribed 28,001 times by 747 Medicare Part D providers in 2023, costing the program $23.9M. At $852 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 388 | Linagliptin/Metformin Hcl (Jentadueto) | $24.3M | 33,018 |
| 389 | Ocrelizumab (Ocrevus) | $24.2M | 639 |
| 390 | Fenofibrate (Fenofibrate) | $24.2M | 670,936 |
| 391 | Empaglifloz/Linaglip/Metformin (Trijardy Xr) | $23.9M | 28,001 |
| 392 | Fluticasone Furoate (Arnuity Ellipta) | $23.7M | 74,825 |
| 393 | Lactulose (Lactulose) | $23.6M | 538,677 |
| 394 | Siponimod (Mayzent) | $23.5M | 2,195 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology